Vasoactives in Septic Shock Part II

<p>Vasoactives in Septic Shock Part II</p> <p>Special Guest: Patrick M. Wieruszewski, Pharm.D., BCCCP</p> <p> </p> <p>Reference List: <a href='https://pharmacytodose.files.wordpress.com/2021/12/vasoactives-in-septic-shock-ii-references.pdf'>https://pharmacytodose.files.wordpress.com/2021/12/vasoactives-in-septic-shock-ii-references.pdf</a></p> <p> </p> <p>02:51 – Background into vasodilatory shock and its outcomes; 04:14 – Signs/symptoms of septic shock; 05:09 – Norepinephrine as first-line vasopressor; 09:05 – Using second-line vasopressors; 17:04 – Human physiology and hemodynamics; 21:02 – More important: time to treatment or vasopressor choice; 22:16 – Taking biomarkers/genetic markers from the research lab to clinical practice; 28:22 – Vasopressin use in septic shock; 43:14 – Angiotensin II updates; 66:00 – Epinephrine in septic shock; 69:32 – Vasopressor stewardship; 72:40 – One wish for septic shock management</p> <p> </p> <p>PharmacyToDose.Com</p> <p>@PharmacyToDose on Twitter</p> <p><a href='mailto:PharmacyToDose@Gmail.com'>PharmacyToDose@Gmail.com</a></p>